Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 8/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 7/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042961 | 0.90 | HTR6 (0.45) | HTR6KDM4EMEN1KMT2AHTT | |
| SCHEMBL5037857 | 0.89 | ENPP3 (0.40) | ENPP3ENPP1ENPP2HTR6KDM4E | |
| SCHEMBL5033442 | 0.88 | NPC1 (0.38) | ENPP3ENPP1ENPP2HTR6MAPT | |
| SCHEMBL5033414 | 0.87 | MAPT (0.41) | HTR6MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL7148418 | 0.86 | GALR2 (0.47) | HTR6MAPTMEN1KMT2A | |
| SCHEMBL5033747 | 0.84 | ENPP3 (0.39) | ENPP3ENPP1ENPP2HTR6 | |
| SCHEMBL5037881 | 0.83 | LMNA (0.43) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL5041016 | 0.82 | MAPT (0.46) | MAPTKDM4EHTTALDH1A1 | |
| SCHEMBL5036480 | 0.82 | NPC1 (0.53) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL5042870 | 0.82 | ENPP3 (0.48) | ENPP3ENPP1ENPP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | claimed |
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | ENPP3 2927/4885ENPP1 3915/4885ENPP2 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.